TAKEDA PHARMACEUTICAL COMPANY LIMITED Financials Takeda Pharmaceutical Company Limited Sapporo S.E.
Equities
4502
JP3463000004
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,300 JPY | -1.15% |
|
-.--% | +8.18% |
Valuation
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 7,029,161 | 5,153,364 | 6,229,971 | 5,423,454 | 6,762,204 | 6,498,524 | - | - |
| Enterprise Value (EV) 1 | 12,054,743 | 9,609,054 | 9,862,522 | 8,919,170 | 10,611,015 | 10,950,330 | 10,687,037 | 10,335,859 |
| P/E ratio | 40 x | 118 x | 16.6 x | 23.8 x | 21.3 x | 45.4 x | 64.1 x | 28.4 x |
| Yield | 3.98% | 5.44% | 4.52% | 5.15% | 4.14% | 4.49% | 4.69% | 4.81% |
| Capitalization / Revenue | 3.35 x | 1.57 x | 1.95 x | 1.52 x | 1.68 x | 1.54 x | 1.52 x | 1.5 x |
| EV / Revenue | 5.75 x | 2.92 x | 3.08 x | 2.5 x | 2.63 x | 2.57 x | 2.5 x | 2.38 x |
| EV / EBITDA | 25.3 x | 14 x | 9.23 x | 8.54 x | 9.19 x | 11.6 x | 9.7 x | 8.65 x |
| EV / FCF | -4.81 x | 9.99 x | 16 x | 8.92 x | 28.7 x | 43.4 x | 15.7 x | 15.7 x |
| FCF Yield | -20.8% | 10% | 6.26% | 11.2% | 3.49% | 2.31% | 6.39% | 6.38% |
| Price to Book | 1.36 x | 1.09 x | 1.2 x | 0.95 x | 1.06 x | 0.9 x | 0.92 x | 0.95 x |
| Nbr of stocks (in thousands) | 1,554,780 | 1,557,849 | 1,563,355 | 1,550,444 | 1,554,530 | 1,568,934 | - | - |
| Reference price 2 | 4,521 | 3,308 | 3,985 | 3,498 | 4,350 | 4,142 | 4,142 | 4,142 |
| Announcement Date | 19-05-14 | 20-05-13 | 21-05-11 | 22-05-11 | 23-05-11 | 24-05-09 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,097,200 | 3,291,200 | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,268,729 | 4,339,235 |
| EBITDA 1 | 477,415 | 684,057 | 1,068,940 | 1,043,995 | 1,154,905 | 942,077 | 1,101,766 | 1,194,359 |
| EBIT 1 | 205,000 | 100,400 | 509,269 | 460,844 | 490,505 | 214,100 | 292,184 | 434,785 |
| Operating Margin | 9.77% | 3.05% | 15.93% | 12.91% | 12.18% | 5.02% | 6.84% | 10.02% |
| Earnings before Tax (EBT) 1 | 94,896 | -60,754 | 366,235 | 302,571 | 375,090 | 52,791 | 112,443 | 304,432 |
| Net income 1 | 109,100 | 44,200 | 376,005 | 230,059 | 317,017 | 144,067 | 103,058 | 230,895 |
| Net margin | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.41% | 5.32% |
| EPS 2 | 113.0 | 28.00 | 240.7 | 147.1 | 204.3 | 92.09 | 64.64 | 145.7 |
| Free Cash Flow 1 | -2,507,219 | 961,871 | 617,401 | 999,853 | 370,054 | 252,482 | 682,369 | 659,391 |
| FCF margin | -119.55% | 29.23% | 19.31% | 28.01% | 9.19% | 5.92% | 15.99% | 15.2% |
| FCF Conversion (EBITDA) | - | 140.61% | 57.76% | 95.77% | 32.04% | 26.8% | 61.93% | 55.21% |
| FCF Conversion (Net income) | - | 2,176.18% | 164.2% | 434.61% | 116.73% | 175.25% | 662.12% | 285.58% |
| Dividend per Share 2 | 180.0 | 180.0 | 180.0 | 180.0 | 180.0 | 188.0 | 194.3 | 199.3 |
| Announcement Date | 19-05-14 | 20-05-13 | 21-05-11 | 22-05-11 | 23-05-11 | 24-05-09 | - | - |
1JPY in Million2JPY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: Marzo | 2020 S1 | 2020 S2 | 2021 S1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 S1 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 S1 | 2025 Q3 | 2025 Q4 | 2026 S1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,660,200 | 1,631,000 | 1,590,785 | 844,797 | 1,794,400 | 901,294 | 873,289 | 972,465 | 1,002,340 | 1,974,800 | 1,096,551 | 956,200 | 1,058,618 | 1,043,089 | 2,101,707 | 1,111,200 | 1,050,869 | 1,073,112 | 1,080,400 | 2,126,400 | 1,139,257 | 1,062,529 | 2,137,000 |
| EBITDA 1 | - | - | - | - | - | - | - | - | - | - | - | 249,972 | 340,072 | 133,355 | - | 291,975 | 176,675 | 320,925 | 282,725 | - | 368,925 | 202,525 | - |
| EBIT 1 | 50,300 | 50,100 | 215,588 | 97,448 | 346,000 | 116,484 | -1,619 | 150,515 | 104,485 | 255,000 | 146,990 | 88,600 | 168,571 | -49,341 | 119,230 | 104,900 | -10,055 | 87,880 | 73,125 | 137,550 | 74,350 | 29,175 | 239,500 |
| Operating Margin | 3.03% | 3.07% | 13.55% | 11.54% | 19.28% | 12.92% | -0.19% | 15.48% | 10.42% | 12.91% | 13.4% | 9.27% | 15.92% | -4.73% | 5.67% | 9.44% | -0.96% | 8.19% | 6.77% | 6.47% | 6.53% | 2.75% | 11.21% |
| Earnings before Tax (EBT) 1 | -27,557 | -33,197 | 125,561 | 61,447 | 284,425 | 72,193 | -54,047 | 155,473 | 64,549 | 220,022 | 107,153 | 47,900 | 135,033 | -95,980 | 39,053 | 61,300 | -47,500 | 60,840 | 44,187 | 57,650 | 35,554 | -8,513 | 156,500 |
| Net income 1 | 33,200 | 11,000 | 86,548 | -16,778 | 183,600 | 57,769 | -11,358 | 105,014 | 61,786 | 166,800 | 119,127 | 31,100 | 89,395 | -48,030 | 41,365 | 105,700 | -3,000 | 54,116 | 40,154 | 59,800 | 33,654 | -2,013 | 120,500 |
| Net margin | 2% | 0.67% | 5.44% | -1.99% | 10.23% | 6.41% | -1.3% | 10.8% | 6.16% | 8.45% | 10.86% | 3.25% | 8.44% | -4.6% | 1.97% | 9.51% | -0.29% | 5.04% | 3.72% | 2.81% | 2.95% | -0.19% | 5.64% |
| EPS 2 | 21.00 | - | 55.45 | -10.27 | 117.0 | 37.01 | -6.950 | 67.94 | 40.06 | 108.0 | 76.70 | 20.03 | 57.51 | -31.00 | 26.51 | 67.38 | -1.920 | 32.13 | 23.80 | 47.50 | 24.35 | -6.569 | 76.80 |
| Dividend per Share 2 | 90.00 | - | 90.00 | - | 90.00 | - | - | - | - | - | - | - | - | 94.00 | 94.00 | - | 94.00 | - | - | - | - | - | - |
| Announcement Date | 19-10-31 | 20-05-13 | 20-10-29 | 21-10-28 | 21-10-28 | 22-02-03 | 22-05-11 | 22-07-28 | 22-10-27 | 22-10-27 | 23-02-02 | 23-05-11 | 23-07-27 | 23-10-26 | 23-10-26 | 24-02-01 | 24-05-09 | - | - | - | - | - | - |
1JPY in Million2JPY
Estimates
Balance Sheet Analysis
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 5,025,582 | 4,455,690 | 3,632,551 | 3,495,716 | 3,848,811 | 4,385,952 | 4,188,513 | 3,837,335 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 10.53 x | 6.514 x | 3.398 x | 3.348 x | 3.333 x | 4.656 x | 3.802 x | 3.213 x |
| Free Cash Flow 1 | -2,507,219 | 961,871 | 617,401 | 999,853 | 370,054 | 252,482 | 682,369 | 659,391 |
| ROE (net income / shareholders' equity) | 3% | 0.9% | 7.6% | 4.2% | 5.3% | 2.1% | 1.42% | 3.17% |
| ROA (Net income/ Total Assets) | 1.06% | -0.46% | 2.85% | 2.32% | 2.76% | 0.36% | 0.82% | 1.93% |
| Assets 1 | 10,334,963 | -9,710,018 | 13,209,937 | 9,918,859 | 11,467,260 | 39,661,656 | 12,574,212 | 11,944,912 |
| Book Value Per Share 2 | 3,319 | 3,032 | 3,309 | 3,666 | 4,087 | 4,636 | 4,503 | 4,347 |
| Cash Flow per Share 2 | 397.0 | 403.0 | 599.0 | 520.0 | 632.0 | 557.0 | 683.0 | 669.0 |
| Capex 1 | 134,114 | 217,710 | 236,468 | 186,037 | 633,689 | 480,730 | 646,300 | 291,364 |
| Capex / Sales | 6.39% | 6.61% | 7.39% | 5.21% | 15.73% | 11.27% | 15.14% | 6.71% |
| Announcement Date | 19-05-14 | 20-05-13 | 21-05-11 | 22-05-11 | 23-05-11 | 24-05-09 | - | - |
1JPY in Million2JPY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
4,142
JPY
Average target price
4,768
JPY
Spread / Average Target
+15.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +41.96% | 630B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 298B | |
| +18.02% | 246B | |
| +1.27% | 225B | |
| +11.95% | 218B | |
| +3.68% | 160B | |
| -4.38% | 156B |
- Stock Market
- Equities
- 4502 Stock
- 4502 Stock
- Financials Takeda Pharmaceutical Company Limited
